Cagrilintide Amylin Receptor Research Guide 2026 — Molecular Profile, DACRA Mechanism & Verification

Cagrilintide is a synthetic, long-acting amylin analogue, and it belongs to a class of research molecules that has drawn intense interest precisely because of the receptor system it engages rather than any single downstream endpoint. Amylin is a 37-amino-acid peptide hormone co-secreted with insulin, and its receptors are among the more unusual constructs in G protein–coupled receptor biology: they are not standalone proteins but complexes assembled from the calcitonin receptor together with accessory proteins. For laboratories modeling energy-metabolism signaling, satiety-pathway pharmacology, or the structural biology of peptide-receptor engagement, a stabilized, well-characterized amylin analogue is a valuable probe — which is why cagrilintide has become a reference compound in preclinical amylin research.

This guide is written for qualified laboratory researchers sourcing cagrilintide as a research compound. It covers the molecular profile, the mechanism at the receptor and pathway level as described in the published literature, representative preclinical data, real citations verifiable through PubMed and PubMed Central, in-vitro research applications, how to evaluate the analytical documentation that should accompany a peptide of this complexity, and the current U.S. regulatory context as of July 2026.

For in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use.

Section 1 — Molecular Profile

Cagrilintide is a lipidated, synthetically engineered amylin analogue built on a pramlintide-like backbone. The single most important structural fact about it is that it is a peptide of substantial size carrying a fatty-acid modification — a design choice that dominates both how it must be handled analytically and how it behaves as a research tool.

• Compound name: Cagrilintide
• Research designations: AM833; NN9838; NNC0174-0833
• CAS number: 1415456-99-3 (peptide free base; note that acetate and other salt forms are assigned separately and reported masses vary by form)
• Molecular formula: C₁₉₄H₃₁₂N₅₄O₅₉S₂ (free base)
• Molecular weight: ≈ 4,409 Da
• Length: 37 amino acids
• Structural class: acylated (lipidated) amylin analogue; dual amylin/calcitonin receptor agonist (DACRA)
• Key modifications: substitutions on a pramlintide-type scaffold, a disulfide-bridged N-terminal ring, and N-terminal acylation with a C20 eicosanedioic (fatty diacid) chain attached through a γ-glutamic-acid linker
• Appearance: typically supplied as a lyophilized powder; reconstituted in an appropriate aqueous buffer for in-vitro work

Two sourcing details follow directly from the structure. First, the C20 fatty-diacid acylation is not cosmetic chemistry — it is the feature that extends the molecule’s stability and duration relative to native amylin, and it is also a point where synthesis can go wrong. Incomplete acylation, wrong-linker byproducts, or free (non-conjugated) peptide are exactly the kinds of impurities that a purity assay must resolve. Second, cagrilintide contains an intramolecular disulfide bond forming its N-terminal loop; correct disulfide formation is part of the identity of the molecule, and misfolded or reduced variants are a real analytical question for any batch. A complete certificate should therefore reflect both purity and confirmed identity, not a purity percentage alone.

Because cagrilintide is a ~4,409 Da peptide, its mass-spectrometry signature is a multiply-charged envelope characteristic of a large peptide — not the single clean cation of a small molecule. This is why cagrilintide should be evaluated with peptide-appropriate analytical expectations: identity confirmation, sequence-consistent mass, and resolution of closely related peptide impurities.

Section 2 — Mechanism (Pathway Language)

Cagrilintide is studied as a dual amylin/calcitonin receptor agonist. The published mechanistic literature describes it strictly at the level of receptor engagement and downstream signaling pathways — not at the level of any clinical endpoint.

The receptor system it targets. Amylin receptors are heteromeric complexes. The core calcitonin receptor (CTR) associates with receptor-activity-modifying proteins (RAMP1, RAMP2, or RAMP3) to generate the three amylin-receptor phenotypes designated AMY1, AMY2, and AMY3. Cagrilintide is described in the literature as engaging these amylin receptors while retaining agonism at the calcitonin receptor itself — the “dual” character that gives the DACRA class its name. This receptor architecture is reviewed in depth in the foundational amylin pharmacology literature (Hay et al., 2015).

Central pathway engagement. Native amylin signaling has been studied primarily in the context of hindbrain and hypothalamic circuits that participate in satiety and energy-metabolism signaling, along with effects on gastric-emptying and glucagon-regulation pathways in preclinical systems. Cagrilintide is used as a long-acting probe of this same receptor system. A 2025 preclinical study using receptor-knockout models reported that the bodyweight-lowering effect of cagrilintide in mice was dependent specifically on brain amylin receptors AMY1 and AMY3 — direct genetic evidence tying the compound’s action to defined receptor subtypes rather than to a diffuse mechanism (Carvas et al., 2025).

Structural basis of binding. In 2025, a cryo-EM structural study resolved how cagrilintide binds across the calcitonin and amylin receptor complexes, describing the contacts and dynamic features that underlie its engagement of the CTR-plus-RAMP architecture (Nature Communications, 2025). This structural work is the kind of research use for which a stable, well-defined amylin analogue is essential.

This article describes cagrilintide strictly at the receptor and pathway level. It is studied for its agonism at amylin and calcitonin receptors and the associated signaling in controlled preclinical systems; no human outcome, therapeutic, or physiological benefit is claimed or implied.

Section 3 — Preclinical Research Data

The cagrilintide literature is built on receptor-binding and signaling assays, rodent pharmacology, and structural biology. Every result below is a preclinical measurement in an experimental system.

Discovery and structure-activity work. The medicinal-chemistry program that produced cagrilintide was published in full, describing the design rationale, the structure–activity relationships across a series of acylated analogues, and the preclinical pharmacology that selected the final compound (Kruse et al., 2021). In that work, cagrilintide was reported to reduce food intake in rats over a multi-day window following a single low-nanomolar-per-kilogram dose — a prolonged preclinical readout consistent with the extended half-life engineered into the molecule. These are described as measurements in a rodent model.

Receptor-subtype dependence. The 2025 knockout study reported that subchronic cagrilintide administration in mice reduced food intake and bodyweight, and that these effects were lost when amylin receptors AMY1 and AMY3 were disrupted in the brain — with the study also noting the reduction fell on relative fat mass while relative lean mass was maintained in the model (Carvas et al., 2025). This is a mechanistic, genetics-based result: it localizes the compound’s activity to specific receptor subtypes in a preclinical system.

Structural pharmacology. The 2025 cryo-EM work characterized the binding poses and dynamic behavior of cagrilintide at the calcitonin and amylin receptors, providing atomic-level context for how the analogue engages this receptor family (Nature Communications, 2025).

Clinical-stage context. Cagrilintide has also been investigated in human clinical trials as an investigational agent (for example, the dose-finding work reported by Lau et al., 2021). Those trials are cited here only to establish that the molecule has advanced to clinical-stage investigation as a drug candidate; they do not describe the research-compound material discussed in this guide, and their endpoints are not represented as outcomes of any PYXAX product.

Across all of these, the interpretive constraint is the same: results are model-specific, and preclinical receptor and rodent findings do not transfer to human physiology. This is preclinical and structural data about a receptor-targeting peptide.

Section 4 — Published Literature (Verifiable Citations)

The following are real, published references retrievable through PubMed, PubMed Central (PMC), or the publishing journal. Researchers are encouraged to read the primary sources directly.

• Kruse T, Hansen JL, Dahl K, et al. “Development of Cagrilintide, a Long-Acting Amylin Analogue.” Journal of Medicinal Chemistry. 2021;64(15):11183–11194 (doi:10.1021/acs.jmedchem.1c00565) — the discovery, structure–activity, and preclinical pharmacology paper for cagrilintide.
• Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. “Amylin: Pharmacology, Physiology, and Clinical Potential.” Pharmacological Reviews. 2015;67(3):564–600 (doi:10.1124/pr.115.010629) — the foundational review of amylin receptor architecture (CTR + RAMP) and amylin pharmacology.
• Carvas AO, Leuthardt A, Kulka P, et al. “Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.” EBioMedicine. 2025 (doi:10.1016/j.ebiom.2025.105836; PMC12270663) — receptor-knockout evidence localizing the compound’s preclinical activity to AMY1 and AMY3.
• “Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors.” Nature Communications. 2025;16 (doi:10.1038/s41467-025-58680-y; PMC11982234) — cryo-EM structural characterization of cagrilintide at the receptor complexes.
• Lau DCW, Erichsen L, Francisco AM, et al. “Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.” The Lancet. 2021;398(10317):2160–2172 (doi:10.1016/S0140-6736(21)01751-7) — cited only as evidence of clinical-stage investigation of the molecule as a drug candidate.

Citing real primary literature is a core part of the PYXAX research-context standard. Two caveats apply specifically to this literature. First, cagrilintide is an investigational drug candidate developed by a single originator, and much of the compound-specific pharmacology traces to that program and its collaborators; independent replication of specific endpoints is still accumulating. Second, a great deal of secondary vendor material restates the clinical-trial bodyweight findings as though they described a research compound’s properties — they do not. Verify each claim against a retrievable primary source rather than a secondary summary, including this one.

Section 5 — Research Applications (In-Vitro Use Cases)

Within qualified laboratory settings, cagrilintide is used as a reference and probe compound in several categories of in-vitro and preclinical work:

• Amylin-receptor pharmacology — as a long-acting agonist reference for characterizing AMY1/AMY2/AMY3 (CTR + RAMP1/2/3) signaling in cell-based assays.
• Calcitonin-receptor signaling studies — as a dual-agonist probe for comparing CTR versus amylin-receptor engagement.
• Receptor structural biology — as a stable, well-defined ligand for cryo-EM and binding studies of the calcitonin/amylin receptor family.
• RAMP-complex research — as a tool to study how receptor-activity-modifying proteins reshape ligand pharmacology at the calcitonin receptor.
• Comparative amylin-analogue screening — as a benchmark long-acting analogue when profiling other amylin-class research peptides in preclinical systems.
• Peptide-stability and formulation research — as a model acylated peptide for studying how fatty-diacid lipidation affects handling and analytical behavior.

Each application is an in-vitro or preclinical research use. Compounds supplied for research must not be used in any human or veterinary context.

Section 6 — How to Evaluate a Source

Because cagrilintide is a large, acylated, disulfide-containing peptide, its documentation should be read with peptide-appropriate expectations — and its structural complexity makes complete documentation more, not less, important.

Step 1 — Confirm the exact molecule and form. The certificate of analysis (COA) should identify the material as cagrilintide, state the salt/acylation form, and give the corresponding molecular weight (≈ 4,409 Da for the free base). Because acylated peptides can be supplied in different salt forms, a milligram figure is only fully meaningful once the form is specified.

Step 2 — Confirm the testing laboratory is named. “Third-party tested” is meaningless without a named, accredited laboratory. Look for an ISO/IEC 17025-accredited facility and a COA that names the lab that tested the specific batch.

Step 3 — Confirm identity by mass spectrometry. For a ~4,409 Da peptide, LC-MS should return a sequence-consistent mass via a multiply-charged envelope, confirming both the peptide and its acylation. A COA reporting only a purity percentage without an identity mass is incomplete.

Step 4 — Read the chromatogram for the right impurities. HPLC should show a single dominant peak. For an acylated peptide the relevant impurity questions include non-acylated (free) peptide, wrong-linker byproducts, deletion sequences, and disulfide-misfolded variants — closely related species that a good method must resolve. Purity without an identity method does not establish that the main peak is the intended compound.

Step 5 — Verify lot specificity and a complete panel. The batch number on the COA must match the vial label and correspond to the production lot — not a single historical test applied across an entire catalog. A COA you can verify independently, through a QR-linked laboratory portal or a searchable community database, is the standard to hold. For cell-based work, purity and identity should be accompanied by endotoxin and heavy-metal data, both of which can confound sensitive assay systems.

Section 7 — Regulatory Context (July 2026)

The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet July 23–24, 2026 at the FDA’s White Oak campus to consider a set of peptides for potential inclusion on the Section 503A Bulk Drug Substances List, with a docket that includes BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax, and Epitalon.

Cagrilintide is not on that docket. This is worth stating precisely, because absence from a review list is easily misread in both directions. It does not mean cagrilintide has been cleared, endorsed, or approved for any compounding or clinical use, and it equally does not mean the compound has been restricted. Cagrilintide is an investigational drug candidate that has not received FDA approval; as supplied for laboratory work it exists in the research-compound category, and its status is unchanged by the outcome of the July peptide review.

PCAC recommendations are advisory only and are not final until the FDA issues its own determination. This review concerns pharmacy compounding permissions; it does not constitute FDA approval of any compound as a pharmaceutical drug. Researchers remain responsible for compliance with all applicable regulations in their jurisdiction. (See the PYXAX FDA peptide reclassification and peptide-compliance landscape guides for the full picture.)

Section 8 — PYXAX Verification Standard

Every PYXAX batch is independently third-party tested by accredited laboratories including ILS Labs, Krause Analytical, and Janoshik. Batch-specific COAs are published for every lot, naming the accredited lab that tested that batch.

Testing panel:

• Chromatographic purity by HPLC
• Molecular identity by LC-MS
• Endotoxin (USP <85> LAL method)
• Heavy metals by ICP-MS
• QR-verified, batch-specific COA published for every lot

Lot-specific documentation. Every production lot receives its own batch number, matching the COA in the PYXAX COA Library, so researchers can confirm identity — including exact form and species supplied — before ordering.

Community verification. Select lots are submitted to Janoshik Analytical, with results publicly searchable by batch number — no vendor contact required. Founding batches were verified through Krause Analytical (accredited US laboratory), and ongoing production lots are tested across the accredited-laboratory network described above.

View PYXAX Cagrilintide →
View COA Library →
Read The PYXAX Standard →

Additional resources: pyxax.com/shop/ · pyxax.com/standard/

All PYXAX compounds are supplied strictly for in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use. Not for diagnostic procedures. These statements have not been evaluated by the FDA. Researchers are responsible for compliance with all applicable laws and regulations governing the use of research compounds in their jurisdiction.